Ariella Raban - Kamada VP HR
| KMDA Stock | USD 8.19 0.05 0.61% |
Insider
Ariella Raban is VP HR of Kamada
| Age | 48 |
| Address | 2 Holzman Street, Rehovot, Israel, 7670402 |
| Phone | 972 8 940 6472 |
| Web | https://www.kamada.com |
Kamada Management Efficiency
The company has return on total asset (ROA) of 0.0476 % which means that it generated a profit of $0.0476 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0786 %, meaning that it created $0.0786 on every $100 dollars invested by stockholders. Kamada's management efficiency ratios could be used to measure how well Kamada manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.06. The current year's Return On Capital Employed is expected to grow to 0.06. At present, Kamada's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 226.9 M, whereas Total Current Assets are forecasted to decline to about 116.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Janelle Strop | Tactile Systems Technology | N/A | |
| CCFP DipSportMed | Evolus Inc | 60 | |
| MBA MBA | Rocket Pharmaceuticals | 43 | |
| Patrick Schneider | QuantumSi | N/A | |
| Aleksandra MD | PureTech Health PLC | N/A | |
| , Langer | PureTech Health PLC | 77 | |
| MBA MBA | Solid Biosciences LLC | 65 | |
| CPA CPA | Rocket Pharmaceuticals | 51 | |
| Kevin Giordano | Rocket Pharmaceuticals | N/A | |
| Erin Brennan | Solid Biosciences LLC | 51 | |
| Bennett MD | PureTech Health PLC | 84 | |
| MD ODonnell | Tactile Systems Technology | N/A | |
| David Erickson | Evolus Inc | N/A | |
| Todd Rearick | QuantumSi | N/A | |
| Caitlin Lowie | Solid Biosciences LLC | N/A | |
| Sandra Beaver | Evolus Inc | 47 | |
| Paul Herzich | Solid Biosciences LLC | 48 | |
| Gaurav MD | Rocket Pharmaceuticals | 51 | |
| Michael McKenna | QuantumSi | 62 | |
| David Elmaleh | PureTech Health PLC | 78 | |
| Eric Pauls | Tactile Systems Technology | 49 | |
Management Performance
| Return On Equity | 0.0786 | ||||
| Return On Asset | 0.0476 |
Kamada Leadership Team
Elected by the shareholders, the Kamada's board of directors comprises two types of representatives: Kamada inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kamada. The board's role is to monitor Kamada's management team and ensure that shareholders' interests are well served. Kamada's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kamada's outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Tsur, Co-Founder and Deputy Executive Chairman | ||
| LLB BA, General VP | ||
| Boris Gorelik, Vice Programs | ||
| Liron Reshef, Vice Resources | ||
| Chaime Orlev, Chief Officer | ||
| Yifat Esq, Gen Legal | ||
| Amir London, Chief Officer | ||
| Ariella Raban, VP HR | ||
| Eran Nir, Chief Officer | ||
| Hanni Neheman, Vice Sales | ||
| Shavit Beladev, Vice Plasma | ||
| Jon Knight, Vice Operations |
Kamada Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kamada a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0786 | ||||
| Return On Asset | 0.0476 | ||||
| Profit Margin | 0.12 % | ||||
| Operating Margin | 0.17 % | ||||
| Current Valuation | 418.85 M | ||||
| Shares Outstanding | 57.68 M | ||||
| Shares Owned By Insiders | 7.19 % | ||||
| Shares Owned By Institutions | 49.96 % | ||||
| Number Of Shares Shorted | 85.92 K | ||||
| Price To Earning | 11.71 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kamada offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kamada's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kamada Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kamada Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kamada. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Kamada Stock refer to our How to Trade Kamada Stock guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kamada. Expected growth trajectory for Kamada significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kamada assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.286 | Earnings Share 0.35 | Revenue Per Share | Quarterly Revenue Growth 0.126 | Return On Assets |
Understanding Kamada requires distinguishing between market price and book value, where the latter reflects Kamada's accounting equity. The concept of intrinsic value - what Kamada's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Kamada's price substantially above or below its fundamental value.
Understanding that Kamada's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kamada represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Kamada's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.